Table 1.
Ingenuity pathways in kidney affected by OVE diabetes and/or OVE-ACKR2 diabetes.
| Ingenuity canonical pathway | OVE versus FVB | OVE-ACKR2 versus FVB | ||
|---|---|---|---|---|
| p value | Ratio∗ | p value | Ratio∗ | |
| Diseases-specific pathways | ||||
| Hepatic fibrosis | 4.27E − 10 | 26/147 | 0.003 | 6/147 |
| Atherosclerosis signaling | 7.76E − 10 | 23/129 | NS | 2/129 |
| Altered T cell and B cell signaling in rheumatoid arthritis | 3.38E − 08 | 17/92 | NS | 1/92 |
| Graft-versus-host disease signaling | 3.71E − 06 | 10/50 | NS | 1/50 |
| Glioma invasiveness signaling | 6.31E − 06 | 12/60 | NS | 1/60 |
| Cellular immune response | ||||
| Communication between innate and adaptive immune cells | 3.89E − 10 | 18/109 | NS | 1/109 |
| Dendritic cell maturation | 2.39E − 08 | 23/185 | NS | 0 |
| Altered T cell and B cell signaling in rheumatoid arthritis | 3.38E − 08 | 17/92 | NS | 1/92 |
| Pattern recognition receptors of bacteria and viruses | 3.38E − 08 | 19/106 | NS | 2/106 |
| Leukocyte extravasation signaling | 6.61E − 08 | 27/199 | NS | 2/199 |
| Humoral immune response | ||||
| Complement system | 7.94E − 11 | 13/35 | NS | 1/35 |
| B cell development | 5.49E − 06 | 8/36 | NS | 0 |
| NF-κB signaling | 7.94E − 05 | 19/175 | NS | 0 |
| p38 MAPK signaling | 0.00017 | 14/106 | NS | 0 |
| Antigen presentation pathway | 0.0002 | 7/40 | NS | 0 |
| Intracellular and second messenger signaling | ||||
| p38 MAPK signaling | 0.0002 | 14/106 | NS | 0 |
| Role of NFAT in regulation of the immune response | 0.002 | 16/198 | NS | 0 |
| Nitrogen metabolism | 0.0037 | 6/120 | NS | 1/120 |
| Histidine metabolism | 0.0044 | 7/112 | 0.00012 | 5/112 |
| Arginine and proline metabolism | 0.0141 | 8/176 | 0.00676 | 4/176 |
| Cellular stress and injury | ||||
| Intrinsic prothrombin activation pathway | 1.55E − 05 | 8/32 | NS | 1/32 |
| Coagulation system | 1.73E − 05 | 9/38 | NS | 0 |
| Extrinsic prothrombin activation pathway | 5.25E − 05 | 6/20 | NS | 0 |
| p38 MAPK signaling | 0.00017 | 14/106 | NS | 0 |
| HMGB1 signaling | 0.00245 | 11/100 | NS | 0 |
| Cytokine signaling | ||||
| Dendritic cell maturation | 2.39E − 08 | 23/185 | NS | 0 |
| Acute phase response signaling | 8.91E − 08 | 25/177 | 0.00813 | 6/177 |
| TREM1 signaling | 6.92E − 05 | 10/66 | NS | 0 |
| IL-8 signaling | 7.41E − 05 | 20/193 | NS | 2/193 |
| NF-κB signaling | 7.94E − 05 | 19/175 | NS | 0 |
| Pathogen-influenced signaling | ||||
| Dendritic cell maturation | 2.39E − 08 | 23/185 | NS | 0 |
| Pattern recognition receptors of bacteria and viruses | 3.38E − 08 | 19/106 | NS | 2/106 |
| Virus entry via endocytic pathways | 0.00014 | 13/100 | NS | 2/100 |
| Clathrin-mediated endocytosis signaling | 0.00019 | 20/195 | NS | 2/195 |
| Caveolar-mediated endocytosis signaling | 0.0015 | 10/85 | NS | 1/85 |
| Nuclear receptor signaling | ||||
| LXR/RXR activation | 1.63E − 13 | 28/136 | 0.0002 | 7/136 |
| TR/RXR activation | 0.0017 | 11/96 | NS | 2/96 |
| Aryl hydrocarbon receptor signaling | 0.0028 | 14/159 | NS | 6/159 |
| Nitrogen metabolism | 0.0037 | 6/120 | NS | 1/120 |
| LPS/IL-1 mediated inhibition of RXR function | 0.0039 | 18/235 | NS | 9/235 |
∗Ratio: RNAs altered versus FVB divided by the number of genes in the pathway. NS, not significant.